World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Homepage

Online Submission

Number of total visits: 30632186

Number of visits today: 6916

Number of downloads: 13060174

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Ebbers SC, Braat AJAT, Moelker A, Stokkel MPM, Lam MGEH, Barentsz MW. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial). Trials 2020;21:141. [PMID: 32024533 DOI: 10.1186/s13063-019-3888-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]

For:

Ebbers SC, Braat AJAT, Moelker A, Stokkel MPM, Lam MGEH, Barentsz MW. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial). Trials 2020;21:141. [PMID: 32024533 DOI: 10.1186/s13063-019-3888-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]

Number	Citing Articles
1	Sayman HB, Gulsen F, Sager S, Akgun E, Yeyin N, Bilgic S, Toplutas KN, An F, Beytur F, Oklu R, Aras O. Selective Intra-Arterial Lutetium-177-Labeled Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer: Initial Results. J Vasc Interv Radiol 2021:S1051-0443(21)01443-3. [PMID: 34715321 DOI: 10.1016/j.jvir.2021.10.016] [Reference Citation Analysis]
2	Prado-Wohlwend S, Bernal-Vergara JC, Utrera-Costero A, Cañón-Sánchez JR, Agudelo-Cifuentes M, Bello-Arques P; Endocrinology Working Group of the SEMNIM. Peptide receptor radionuclide therapy with [¹⁷⁷Lu]Lu-DOTA-TATE. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021:S2253-8089(21)00164-6. [PMID: 34920969 DOI: 10.1016/j.remnie.2021.11.001] [Reference Citation Analysis]
3	Minczeles NS, Hofland J, de Herder WW, Brabander T. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy. Curr Oncol Rep 2021;23:46. [PMID: 33721105 DOI: 10.1007/s11912-021-01037-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4	La Salvia A, Espinosa-Olarte P, Riesco-Martinez MDC, Anton-Pascual B, Garcia-Carbonero R. Targeted Cancer Therapy: What's New in the Field of Neuroendocrine Neoplasms? Cancers (Basel) 2021;13:1701. [PMID: 33916707 DOI: 10.3390/cancers13071701] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5	Tai E, Kennedy S, Farrell A, Jaberi A, Kachura J, Beecroft R. Comparison of transarterial bland and chemoembolization for neuroendocrine tumours: a systematic review and meta-analysis. Curr Oncol 2020;27:e537-46. [PMID: 33380868 DOI: 10.3747/co.27.6205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6	Zane KE, Cloyd JM, Mumtaz KS, Wadhwa V, Makary MS. Metastatic disease to the liver: Locoregional therapy strategies and outcomes. World J Clin Oncol 2021; 12(9): 725-745 [PMID: 34631439 DOI: 10.5306/wjco.v12.i9.725] [Reference Citation Analysis]
7	Thakral P, Sen I, Das SS, Manda D, Cb V, Malik D. Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease. Br J Radiol 2021;:20210403. [PMID: 34357794 DOI: 10.1259/bjr.20210403] [Reference Citation Analysis]
8	Ahenkorah S, Cassells I, Deroose CM, Cardinaels T, Burgoyne AR, Bormans G, Ooms M, Cleeren F. Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside. Pharmaceutics 2021;13:599. [PMID: 33919391 DOI: 10.3390/pharmaceutics13050599] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]